Arvinas (NASDAQ: ARVN) is a leader in targeted protein degradation, a novel therapeutic modality with the potential to drug previously undruggable targets. The company’s lead asset, bavdegalutamide (ARV-110), is in Phase 3 for metastatic castration-resistant prostate cancer (mCRPC), with top-line data expected in H2 2026. Positive results could lead to a rapid NDA filing and approval, given the high unmet need and prior Fast Track designation.
Beyond bavdegalutamide, Arvinas has a deep pipeline including ARV-471 (vepdegestrant) for breast cancer, partnered with Pfizer, and early-stage programs in neurology and oncology. The PROTAC platform has been validated by multiple partnerships (Pfizer, Bayer, Novartis) and a strong IP position.
Financially, Arvinas had $1.5 billion in cash and equivalents as of Q2 2026, providing runway into 2029. The company is well-capitalized to fund operations and potential commercialization without near-term dilution.
Key Catalysts (12 months):
- Phase 3 bavdegalutamide data in mCRPC (H2 2026) – potential approval and launch.
- Phase 2 data for ARV-471 in combination with Ibrance (palbociclib) in breast cancer (2026).
- Potential partnership or milestone payments from Pfizer on ARV-471.
Key Risks:
- Clinical failure: bavdegalutamide or ARV-471 could miss endpoints, leading to stock decline.
- Competition: other PROTAC companies (e.g., Kymera, C4 Therapeutics) and alternative modalities (e.g., ADCs) may advance faster.
Valuation: Arvinas trades at ~4x cash-adjusted enterprise value to 2027 consensus sales, with significant upside if bavdegalutamide succeeds. Comparable companies with approved assets trade at 6-10x sales, implying 50-100% upside.
Balance Sheet: $1.5B cash, no debt, strong liquidity. Cash burn ~$400M/year, providing >3 years runway.
Disclaimer: This is not financial advice. Investing in biotech stocks carries high risk, including potential total loss. Do your own due diligence.